Virus-Like Particles (VLPs) Technology Platform

Virus-like particles (VLPs) are a class of non-infectious viral particles that are structurally similar to natural viruses but do not contain viral genomes. Due to their safety and immunogenicity, VLPs are widely used in vaccine development and biomedical research, especially in membrane protein research, where VLP systems show important advantages and potential.

1. VLP Structure and Classification

VLPs are particles formed by the assembly of viral structural proteins, with sizes and shapes similar to natural viruses [1]. According to their origin and structural characteristics, VLPs can be divided into various types, including RNA viruses, DNA viruses, and chimeric viruses [2]. VLPs possess the immunogenicity of natural viruses but lack infectivity and replicative capabilities, making them safe and effective vaccine carriers [3].

Figure 1. The diagram of a virus-like particle (VLP) structure.

2. Production Methods for the VLP Technology Platform

The production of virus-like particles (VLPs) involves several steps, including the expression of viral structural proteins, their self-assembly into particles, and purification. Here are the key production methods used in VLP technology platforms:

2.1 Yeast Expression Systems

Example: Saccharomyces cerevisiae

Advantages: High yield, cost-effective, and capable of performing post-translational modifications.

Applications: Used in the production of Hepatitis B VLPs and HPV VLPs.

2.2 Insect Cell Expression Systems

Example: Baculovirus Expression Vector System (BEVS)

Advantages: High expression levels, proper folding and assembly, suitable for complex proteins.

Applications: Widely used for producing VLPs for various vaccines, including HPV and influenza.

2.3 Mammalian Cell Expression Systems

Example: HEK293 and CHO cells

Advantages: Human-like post-translational modifications, high biological activity of the proteins.

Applications: Used for VLPs in vaccines requiring complex glycosylation patterns, such as HIV and influenza.

2.4 Plant-based Expression Systems

Example: Nicotiana benthamiana

Advantages: Low cost, scalability, and lack of human pathogens.

Applications: Used for experimental vaccines and therapeutic proteins

3. VLP-Based Membrane Protein Expression Service Workflow

The process of expressing membrane proteins using virus-like particles (VLPs) involves several critical steps, ensuring the production of high-quality VLPs suitable for research and clinical applications. Here is an overview of the VLP-based membrane protein expression service workflow:

3.1 Gene Cloning and Vector Construction

Gene Cloning: The first step involves cloning the gene encoding the target membrane protein into an appropriate expression vector. Common vectors include plasmids or viral vectors designed for high expression efficiency.

Vector Construction: The cloned gene is then incorporated into the expression vector, which may also include tags for purification and detection.

3.2 Transfection and Protein Expression

Host Cell Selection: Suitable host cells are selected based on the specific requirements of the target protein. Commonly used host cells include yeast, insect cells (such as Sf9 cells), and mammalian cells (such as HEK293 or CHO cells).

Transfection: The constructed vector is introduced into the host cells through transfection methods such as lipofection, electroporation, or viral infection.

Expression Optimization: Conditions such as temperature, medium composition, and induction agents are optimized to enhance protein expression and ensure proper folding and assembly.

3.3 VLP Assembly

Self-Assembly: Once expressed, the structural proteins and the target membrane protein self-assemble into VLPs within the host cells. This process might require fine-tuning to achieve optimal assembly efficiency.

Monitoring Assembly: Techniques such as dynamic light scattering (DLS) and electron microscopy (EM) are used to monitor the size and morphology of the assembled VLPs.

3.4 VLP Harvesting and Purification

Harvesting: VLPs are harvested from the cell culture medium or from cell lysates, depending on the expression system used.

Purification: The harvested VLPs undergo purification processes such as ultracentrifugation, gel filtration chromatography, and ion-exchange chromatography. These methods help remove impurities and concentrate the VLPs to a high purity level.

3.5 VLP Characterization and Quality Control

Characterization: The purified VLPs are characterized for their size, shape, and integrity using techniques like DLS, EM, and analytical ultracentrifugation. Western blotting and mass spectrometry may also be used to confirm the presence and correct assembly of the target membrane protein.

Functional Assays: Biological activity and functionality of the membrane protein within the VLPs are assessed through various assays to ensure they meet the desired specifications.

3.6 Delivery and Post-Delivery Support

Delivery: The purified and characterized VLPs are packaged and delivered to the client along with a detailed experimental report and instructions for use.

Technical Support: Ongoing technical support and consultation are provided to assist the client in effectively using the VLPs for their specific applications, such as vaccine development, drug screening, or structural studies.

Figure 2 Schematic diagram of a VLP-expressed protein

This workflow is designed to provide a standardized and optimized process for VLP-based membrane protein expression, ensuring high-quality results that meet the needs of both research and clinical applications.

4. Advantages of VLPs in Expressing Transmembrane Proteins

VLPs exhibit significant advantages in expressing transmembrane proteins, mainly manifested in the following aspects:

Maintenance of spatial conformation:Transmembrane proteins have complex three-dimensional structures, and their functions often rely on the correct spatial conformation on the cell membrane. Compared to other expression systems, VLPs better simulate the membrane environment of natural viruses, helping maintain the correct spatial conformation and bioactivity of transmembrane proteins[4].

Protein translation and modification:VLPs can be produced through mammalian cell expression systems, which offer higher fidelity in protein translation, folding, and modification, contributing to the correct expression and functionality of transmembrane proteins[5].

Enhanced immunogenicity:VLPs can serve as immunogenic delivery carriers, presenting transmembrane proteins to the immune system in the form of natural viruses. This approach can enhance the immunogenicity of transmembrane proteins, eliciting a more robust immune response[6].

Functional screening:Using VLPs to express transmembrane proteins allows for convenient functional screening, such as measuring transmembrane protein affinity or optimizing antibody affinity. This helps study the biological functions of transmembrane proteins and develop related drugs[7].

The advantages of VLPs in expressing transmembrane proteins help address key issues in transmembrane protein research, such as protein expression, functional screening, and immunogenicity.

5. Research Progress on VLP Systems for Membrane Protein Production

Virus-like particles (VLPs) are non-infectious particles that resemble native viruses in structure but lack viral genetic material. They have found extensive applications in vaccine development, gene delivery, and membrane protein research. Here is an overview of the research progress and specific examples of VLP systems in membrane protein production.

5.1 Efficient Expression and Proper Folding

VLP systems can efficiently express and properly fold membrane proteins in eukaryotic cells, providing a similar environment to native cells for complex post-translational modifications and folding mechanisms.Hepatitis B Virus-like Particles. The Hepatitis B surface antigen (HBsAg) is expressed in yeast or mammalian cells and self-assembles into VLPs, used in Hepatitis B vaccines such as Recombivax HB and Engerix-B[8].

5.2 Vaccine Development

VLPs are widely used in vaccine development due to their ability to mimic the structure of viruses, inducing strong immune responses while being non-infectious and safe[9]. Human Papillomavirus (HPV) Vaccines. The L1 protein of HPV is expressed in insect or yeast cells and self-assembles into VLPs, leading to the development of HPV vaccines like Gardasil and Cervarix, which effectively prevent HPV infections and related cancers. HIV Vaccine Research. HIV envelope proteins gp120 and gp41 are expressed in mammalian cells and self-assemble into VLPs, used in HIV vaccine research to induce strong immune responses and advance HIV vaccine development[10].

5.3 Structural Biology Research

VLPs offer a robust method for the expression and purification of membrane proteins, aiding in crystallography and cryo-electron microscopy (cryo-EM) studies to provide high-resolution structural information.

5.4 Drug Screening

Membrane proteins expressed in VLP systems can be used to create high-throughput screening platforms for potential drug molecules, particularly for G protein-coupled receptors (GPCRs) and ion channels. GPCRs are expressed and incorporated into VLPs in insect or mammalian cells, facilitating high-resolution structural biology studies and drug screening. For example, the β2-adrenergic receptor (β2AR) expressed in VLPs has aided in its structural analysis and ligand screening. Ion Channel Studies[11]. Ion channels such as voltage-gated sodium channels (Nav) are expressed in VLP systems, enabling drug screening and functional studies to understand their roles in nerve and muscle cells[12].

5.5 Gene Editing and Delivery

VLP systems are utilized for delivering CRISPR/Cas9 components efficiently, enabling precise gene editing, especially for targeting membrane protein genes.

6. Future Prospects of VLP Systems for Membrane Protein Production

Virus-like particles (VLPs) have emerged as a transformative tool in biotechnology, particularly for the production and study of membrane proteins. These non-infectious particles, which mimic the structure of viruses, have significant applications in vaccine development, gene delivery, and drug discovery. The future of VLP systems for membrane protein production is promising, with numerous advancements and innovations anticipated in the coming years. This essay explores potential future developments in VLP technology, focusing on key areas such as vaccine development, structural biology, drug discovery, and gene editing.

6.1 Enhanced Production and Purification Techniques

A primary challenge in the widespread adoption of VLP systems is optimizing production and purification processes. Future advancements are likely to focus on improving yield, scalability, and cost-effectiveness. Innovations in bioprocessing techniques, including high-density cell cultures and advanced bioreactors, will significantly enhance VLP production. Additionally, novel purification methods, such as affinity chromatography and membrane-based separation technologies, will improve the efficiency and purity of VLPs, making them more suitable for clinical applications[13].

6.2 Vaccine Development

VLPs have already shown great promise in vaccine development, with successful vaccines against diseases such as hepatitis B and human papillomavirus (HPV). Future research will likely expand the use of VLPs to develop vaccines for a broader range of infectious diseases, including emerging viral infections like Zika, Ebola, and COVID-19. The ability of VLPs to present multiple antigens on their surface makes them an ideal platform for developing multivalent vaccines, capable of providing immunity against several strains or types of a pathogen. Additionally, VLPs can be engineered to incorporate adjuvants, enhancing their immunogenicity and efficacy.

6.3 Structural Biology and Functional Studies

The study of membrane proteins is crucial for understanding cellular processes and developing targeted therapies. VLPs provide an excellent platform for expressing and stabilizing membrane proteins in their native conformations, facilitating structural and functional studies. Advances in cryo-electron microscopy (cryo-EM) and other imaging techniques will enable researchers to obtain high-resolution structures of membrane proteins embedded in VLPs. This will lead to a deeper understanding of protein function and interactions, paving the way for the rational design of new drugs and therapeutic agents[14].

6.4 Drug Discovery and Screening

Membrane proteins, including G protein-coupled receptors (GPCRs) and ion channels, are major targets for drug discovery. VLPs offer a robust system for the high-throughput screening of potential drug candidates. Future developments will focus on creating VLP libraries displaying a wide variety of membrane proteins, allowing for the rapid identification of ligands and inhibitors. Additionally, integrating VLP-based screening with advanced techniques such as artificial intelligence (AI) and machine learning will accelerate the drug discovery process, identifying novel therapeutics with higher specificity and efficacy[15].

6.5 Gene Editing and Delivery

VLPs have shown potential as delivery vehicles for gene editing tools like CRISPR/Cas9. The non-infectious nature and customizable surface properties of VLPs make them suitable for targeted delivery of gene editing components to specific cells or tissues. Future research will explore the use of VLPs for the delivery of not only CRISPR/Cas9 but also other gene editing technologies such as base editors and prime editors. This will enhance the precision and efficiency of gene editing, offering new therapeutic possibilities for genetic disorders and diseases[16][17].

Conclusion

The future of VLP systems for membrane protein production holds significant promise. Enhanced production and purification techniques will improve their scalability and cost-effectiveness. Vaccine development will benefit from the versatility of VLPs in presenting multiple antigens and incorporating adjuvants. Structural biology and functional studies will gain from the high-resolution imaging of membrane proteins in VLPs. Drug discovery will be accelerated by VLP-based screening platforms, while gene editing and delivery will be advanced by VLP-mediated systems. As research progresses, VLP systems will become indispensable in biotechnology and medicine, leading to improved health outcomes and innovative therapies.

References

[1] Noad, R., & Roy, P. (2003). Virus-like particles as immunogens. Trends in Microbiology, 11(9), 438-444.
[2] Grgacic, E. V., & Anderson, D. A. (2006). Virus-like particles: passport to immune recognition. Methods, 40(1), 60-65.
[3] Vicente, T., et al. (2011). Large-scale production and purification of VLP-based vaccines. Journal of Invertebrate Pathology, 107, S42-S48.
[4] Brune, K. D., & Howarth, M. (2018). New routes and opportunities for modular construction of particulate vaccines: stick, click, and glue. Frontiers in Immunology, 9, 1432.
[5] Castilho, A., Beihammer, G., Pfeiffer, C., & Goritzer, K. (2018). An in planta-produced fusion protein eliciting robust antibody response against the major grass pollen allergens Phl p 1 and Phl p 5a. Plant Biotechnology Journal, 16(10), 1736-1745.
[6] Noad, R., & Roy, P. (2003). Virus-like particles as immunogens. Trends in Microbiology, 11(9), 438-444.
[7] Schwarz, B., & Douglas, T. (2015). Development of virus-like particles for diagnostic and prophylactic biomedical applications. Wiley Interdisciplinary Reviews: Nanomedicine and Nanobiotechnology, 7(5), 722-735.
[8] Pushko, P., Pumpens, P., & Grens, E. (2013). Development of virus-like particle technology from small highly symmetric to large complex virus-like particle structures. Intervirology, 56(3), 141-165.
[9] Mohsen, M. O., Zha, L., Cabral-Miranda, G., & Bachmann, M. F. (2017). Major findings and recent advances in virus–like particle (VLP)-based vaccines. Seminars in Immunology, 34, 123-132.
[10] Roldão, A., Mellado, M. C. M., Castilho, L. R., Carrondo, M. J. T., & Alves, P. M. (2010). Virus-like particles in vaccine development. Expert Review of Vaccines, 9(10), 1149-1176.
[11] Grgacic, E. V., & Anderson, D. A. (2006). Virus-like particles: passport to immune recognition. Methods, 40(1), 60-65.
[12] Kushnir, N., Streatfield, S. J., & Yusibov, V. (2012). Virus-like particles as a highly efficient vaccine platform: diversity of targets and production systems and advances in clinical development. Vaccine, 31(1), 58-83.
[13] Lua, L. H. L., Connors, N. K., Sainsbury, F., Chuan, Y. P., Wibowo, N., & Middelberg, A. P. J. (2014). Bioengineering virus-like particles as vaccines. Biotechnology and Bioengineering, 111(3), 425-440.
[14] Grgacic, E. V., & Anderson, D. A. (2006). Virus-like particles: passport to immune recognition. Methods, 40(1), 60-65.
[15] Roy, P., & Noad, R. (2008). Virus-like particles as a vaccine delivery system: myths and facts. Human Vaccines, 4(1), 5-12.
[16] Yañez-Muñoz, R. J., Balaggan, K. S., MacNeil, A., Howe, S. J., Schmidt, M., Smith, A. J., Buch, P., MacLaren, R. E., Anderson, P. N., Barker, S. E., Duran, Y., Bartholomae, C., von Kalle, C., Heckenlively, J. R., Kinnon, C., Ali, R. R., & Thrasher, A. J. (2006). Effective gene therapy with nonintegrating lentiviral vectors. Nature Medicine, 12(3), 348-353.
[17] Merten, O. W., Hebben, M., & Bovolenta, C. (2016). Production of lentiviral vectors. Molecular Therapy - Methods & Clinical Development, 3, 16017.